Rosetta Gets Medicare Coverage for mets2 Assay; Stock Soars
May 16, 2012
Rosetta Gets Medicare Coverage for mets2 Assay; Stock Soars
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Reagent Problem Could Have Affected Rosetta Genomics' Cancer Test Results
November 10, 2010 / GenomeWeb Daily News - Rosetta Revises Deal with Precision to Co-market miRview mets2
October 17, 2012 / GenomeWeb Daily News - Prospective Study Suggests Site-Specific Treatment after BioTheranostics' CUP Testing Improves Survival
October 17, 2012 / Pharmacogenomics Reporter - Rosetta Publishes Data on Cancer of Unknown Primary Origin Test
May 31, 2012 / Gene Silencing News - Rosetta Genomics Regains Nasdaq Compliance
July 21, 2011 / GenomeWeb Daily News